scispace - formally typeset
D

David Cameron

Researcher at University of Oslo

Publications -  1765
Citations -  141776

David Cameron is an academic researcher from University of Oslo. The author has contributed to research in topics: Large Hadron Collider & Breast cancer. The author has an hindex of 154, co-authored 1586 publications receiving 126067 citations. Previous affiliations of David Cameron include Universidade Nova de Lisboa & Cameron International.

Papers
More filters
Journal ArticleDOI

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Shanu Modi, +37 more
- 05 Jun 2022 - 
TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
Journal ArticleDOI

Performance of the ATLAS trigger system in 2015

Morad Aaboud, +2848 more
- 18 May 2017 - 
TL;DR: This paper presents a short overview of the changes to the trigger and data acquisition systems during the first long shutdown of the LHC and shows the performance of the trigger system and its components based on the 2015 proton–proton collision data.
Journal ArticleDOI

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Gabriel N. Hortobagyi, +20 more
- 01 Jul 2018 - 
TL;DR: Improved efficacy outcomes and manageable tolerability observed with first-line ribociclib plus letrozole monotherapy are maintained with longer follow-up, relative to letrozo monotherapy.
Journal ArticleDOI

Search for squarks and gluinos using final states with jets and missing transverse momentum with the Atlas detector in s=7 TeV proton-proton collisions

Georges Aad, +3037 more
- 04 Jul 2011 - 
TL;DR: In this article, a search for squarks and gluinos in final states containing jets, missing transverse momentum and no electrons or muons is presented, and the data were recorded by the ATLAS experiment in sqrt(s) = 7 TeV proton-proton collisions at the Large Hadron Collider.
Journal ArticleDOI

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial

Aron Goldhirsch, +24 more
- 21 Sep 2013 - 
TL;DR: 2 years of adjuvant trastuzumab is not more effective than is 1 year of treatment for patients with HER2-positive early breast cancer, and 1year of treatment provides a significant disease-free and overall survival benefit compared with observation.